病例报告：乌帕替尼治疗年轻的抗 TNF 治疗抵抗性肠贝赫切特病患者获得缓解。
Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet's disease.
机构信息
Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Department of Radiotherapy, Tangdu Hospital of the Air Force Medical University, Xi'an, Shaanxi, China.
出版信息
Front Immunol. 2024 Nov 8;15:1483993. doi: 10.3389/fimmu.2024.1483993. eCollection 2024.
BACKGROUND
The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behçet's disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians.
CASE PRESENTATION
In this case report, we present a patient with refractory intestinal Behçet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib.
CONCLUSION
This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behçet's disease.
背景
肠白塞病的治疗选择有限，治疗效果不一致，这使得其治疗变得复杂，而缺乏标准化指南进一步加剧了临床医生面临的挑战。
病例介绍
在本病例报告中，我们介绍了一位患有难治性肠白塞病的患者，该患者先前使用生物制剂治疗失败。本病例阐明了使用 Janus 激酶（JAK）抑制剂管理这种复杂情况的方法，患者在改用乌帕替尼后实现了黏膜愈合。
结论
本病例强调了乌帕替尼作为治疗困难性肠白塞病的有效替代药物的潜力。
Zotero 插件